Study to Assess the Cosmetic Changes in the Facial Skin After Use of a Topical Retinoid Product in Participants With Moderate to Severe Photodamage

• ClinicalTrials.gov Identifier: NCT03302559
• Recruitment Status: Completed
• First Posted: October 5, 2017
• Results First Posted: June 4, 2019
• Last Update Posted: June 4, 2019
• Sponsor: Allergan
• Information provided by (Responsible Party): Allergan

Study Description

Brief Summary:

This study will assess the cosmetic changes of a cosmetic topical retinoid product in participants with moderate to severe photodamage utilizing non-invasive in vivo skin imaging instrumentation.

Condition or disease	Intervention/treatment	Phase
Skin Care	Other: Retinol Complex 0.5; Other: Facial cleanser; Other: Moisturizing lotion; Other: Sunscreen; Device: Skin Imaging	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 29 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Assessing the Cosmetic Changes in the Facial Skin Utilizing Non-Invasive In Vivo Skin Imaging Instrumentation After Use of a Topical Retinoid Product In Subjects With Moderate to Severe Photodamage
• Actual Study Start Date: September 18, 2017
• Actual Primary Completion Date: April 30, 2018
• Actual Study Completion Date: April 30, 2018

Arms and Interventions

Arm

Intervention/treatment

Experimental: Retinol Complex 0.5; During a 2-week washout period the participant used a basic skin care regimen (SkinMedica facial cleanser in the morning and in the evening, Cetaphil Fragrance Free Moisturizing Lotion in the morning and in the evening and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen in the morning and as needed), followed by the same basic skin care regimen plus SkinMedica Retinol Complex 0.5 applied topically to the face in the evening for 12 Weeks. Assessments of the participant's facial skin were made utilizing investigator clinical grading, digital photography, a spectrophotometer and in vivo skin imaging.

Other: Retinol Complex 0.5; Retinol Complex 0.5 topically in the evening.; Other Name: SkinMedica Retinol Complex 0.5; Other: Facial cleanser; Facial cleanser in the morning and in the evening.; Other Name: SkinMedica Facial Cleanser; Other: Moisturizing lotion; Fragrance free moisturizing lotion in the morning and in the evening.; Other Name: Cetaphil Fragrance Free Moisturizing Lotion; Other: Sunscreen; Sunscreen broad spectrum sun protection factor (SPF) 35 topically in the morning and as needed.; Other Name: SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35; Device: Skin Imaging; Non-invasive in vivo skin imaging will be taken with the VivoSight Dx Optical Coherence Tomography (OCT) and VivaScope 1500

Outcome Measures

Primary Outcome Measures :

1. Change From Baseline in Overall Photodamage Score [ Time Frame: Baseline (Day 1) to Week 12 ]
   The investigator assessed the participant's overall photodamage using a 10-point scale where None (0)= Facial skin is smooth to the touch, without significant fine/coarse line or skin tone unevenness in any areas (periocular, cheeks, forehead and perioral areas) to Severe (7 to 9)= Facial skin shows 3 or more areas (periocular, cheeks, forehead and perioral areas) of significant roughness, skin tone unevenness (red/brown), or fine/coarse lines at Baseline and Week 12. A decrease in score indicates improvement. A negative change from Baseline indicates improvement.
2. Change From Baseline in Appearance of Fine Lines/Wrinkles Score (Forehead, Periocular, Cheeks and Perioral Areas Individually Assessed) [ Time Frame: Baseline (Day 1) to Week 12 ]
   The investigator assessed the participant's appearance of fine lines/wrinkles using a 10-point scale where None (0)= No fine lines/wrinkles present; skin looks completely smooth and wrinkle-free to Severe (7 to 9)= Many coarse lines/wrinkles densely packed together in the treatment area (forehead, periocular, cheeks and perioral areas) at Baseline and Week 12. A decrease in score indicates improvement. A negative change from Baseline indicates improvement.
3. Change From Baseline in Appearance of Coarse Lines/Wrinkles Score (Forehead, Periocular, Cheeks and Perioral Areas Individually Assessed) [ Time Frame: Baseline (Day 1) to Week 12 ]
   The investigator assessed the participant's appearance of coarse lines/wrinkles using a 10-point scale where None (0)= No coarse lines/wrinkles present; skin looks completely smooth and wrinkle-free to Severe (7 to 9)= Many coarse lines/wrinkles densely packed together in the treatment area (forehead, periocular, cheeks and perioral areas) at Baseline and Week 12. A decrease in score indicates improvement. A negative change from Baseline indicates improvement.
4. Change From Baseline in Tactile Roughness Score [ Time Frame: Baseline (Day 1) to Week 12 ]
   The investigator assessed the participant's tactile roughness in the entire face using a 10-point scale where None (0)= No roughness of the treatment area; skin is completely smooth and pliable to Severe (7 to 9)= Marked roughness of the treatment area associated with stiff feeling at Baseline and Week 12. A decrease in score indicates improvement. A negative change from Baseline indicates improvement.

Secondary Outcome Measures :

1. Change From Baseline in Skin Roughness Score Using the Allergan Skin Roughness Visual Scale [ Time Frame: Baseline (Day 1) to Week 12 ]
   The investigator assessed the participant's skin roughness using the Allergan Skin Roughness Visual 5-Point Scale where None (0)= Smooth visual skin texture to Extreme (4)= Extremely coarse visual skin texture, crosshatched deep creases; extreme elastosis at Baseline and Week 12. A decrease in score indicates improvement. A negative change from Baseline indicates improvement.
2. Change From Baseline in Appearance of Fine Lines Score Using the Allergan Fine Lines Visual Scale [ Time Frame: Baseline (Day 1) to Week 12 ]
   The investigator assessed the participant's fine lines using the Allergan Fine Lines Visual 5-Point Scale where None (0)= No fine lines to Diffuse (4)= Diffuse superficial lines; crosshatching at Baseline and Week 12. A decrease in score indicates improvement. A negative change from Baseline indicates improvement.
3. Investigator's Global Improvement Assessment for Overall Photodamage [ Time Frame: Baseline (Day 1) to Week 12 ]
   The investigator assessed the global improvement in the participant's overall photodamage compared to Baseline using a 5-point scale where None (0)= No change or worsening to Complete (4)= Almost complete improvement of the condition with a trace of signs/symptoms remaining (approximately 95% or better overall improvement).
4. Investigator's Global Improvement Assessment for the Appearance of Fine Lines/Wrinkles (Forehead, Periocular, Cheeks, Perioral Areas Individually Assessed) [ Time Frame: Baseline (Day 1) to Week 12 ]
   The investigator assessed the global improvement in the participant's overall appearance of fine lines/wrinkles compared to Baseline using a 5-point scale where None (0)= No change or worsening to Complete (4)= Complete clearing in the appearance of fine lines/wrinkles (approximately 95% or better overall improvement).
5. Investigator's Global Improvement Assessment for the Appearance of Coarse Lines/Wrinkles (Forehead, Periocular, Cheeks, Perioral Areas Individually Assessed) [ Time Frame: Baseline (Day 1) to Week 12 ]
   The investigator assessed the global improvement in the participant's overall appearance of coarse lines/wrinkles compared to Baseline using a 5-point scale where None (0)= No change or worsening to Complete (4)= Complete clearing in the appearance of coarse lines/wrinkles (approximately 95% or better overall improvement).
6. Investigator's Global Improvement Assessment for Tactile Roughness [ Time Frame: Baseline (Day 1) to Week 12 ]
   The investigator assessed the global improvement in the participant's overall tactile roughness compared to Baseline using a 5-point scale where None (0)= No change or worsening to Complete (4)= Complete clearing in the appearance of tactile roughness (approximately 95% or better overall improvement).
7. Change From Baseline in Spectrophotometer L* Value (a Measurement of Skin Brightness) [ Time Frame: Baseline (Day 1) to Week 12 ]
   Triplicate spectrophotometer readings were taken of the participant's face (Normal Skin and Target Lesions) at Baseline and Week 12. L* value scores range from 0=black to 100=white. An increase in the spectrophotometer L* values indicates improvement. A positive change from Baseline indicates improvement.

Eligibility Criteria

• Ages Eligible for Study: 40 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Participants with Fitzpatrick skin type I-IV
• Presence of moderate to severe facial photodamage
• Participants taking hormone replacement or hormones for birth control, willing to stop or change this medication for the duration of the study
• Willingness to cleanse the face and remove all makeup at least 15 minutes prior to each scheduled clinic visit
• Willingness to not use any other products, including self-tanners on their facial skin during the study
• Willingness to avoid as much as possible, direct and prolonged sun exposure for the duration of the study (including tanning beds), especially from 10 AM to 2 PM. Participants are asked to wear protective clothing prior to and during exposure.

Exclusion Criteria:

• Individuals with active symptoms of allergy, cold sore or warts, active psoriasis or eczema, rosacea, sunburn, open wounds, neurotic excoriations, excessive scarring, tattoos, or other skin conditions in the test areas that would interfere with the assessments of this study
• Individuals who are nursing, pregnant, or planning to become pregnant during the study
• Individuals with uncontrolled disease such as diabetes, hypertension, hyper or hypothyroidism, active hepatitis, immune deficiency, or autoimmune
• Individuals who have a pre-existing or dormant dermatologic condition (e.g., psoriasis, atopic dermatitis, rosacea, skin cancer, etc.)
• Individuals who require electrolysis, waxing, or use depilatories on the face during the study
• Chemical peel or microdermabrasion within 4 weeks of study start
• Retin-A®, Retin-A Micro®, Renova®, Avita®,Tazorac®, Avage® or Differin® or other similar prescription drugs within 3 months of study start
• Cosmetic injections (filler and/or toxins, i.e. Juvederm, Radiesse, Botox, etc.), non-ablative laser or fractional laser resurfacing
• Accutane® or other oral retinoid, Ablative procedures (i.e. laser, chemical, cosmetic surgeries) within 12 months of study start
• Participants who have planned surgeries or procedures.

Contacts and Locations

Locations

United States, California

SkinMedica Clinical Research and Innovation Center

Irvine, California, United States, 92612

Sponsors and Collaborators

Allergan

Investigators

• Principal Investigator: Lisa Goberdhan, B.A.; Allergan

  Study Documents (Full-Text)

Documents provided by Allergan:

Study Protocol and Statistical Analysis Plan  [PDF] November 15, 2017

More Information

• Responsible Party: Allergan
• ClinicalTrials.gov Identifier: NCT03302559
• Other Study ID Numbers: SCRIC17-RET05
• First Posted: October 5, 2017
• Results First Posted: June 4, 2019
• Last Update Posted: June 4, 2019
• Last Verified: June 2019

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:

Vitamin A; Retinol palmitate; Sunscreening Agents; Radiation-Protective Agents; Protective Agents; Physiological Effects of Drugs; Dermatologic Agents; Vitamins; Micronutrients; Nutrients; Growth Substances; Antioxidants; Molecular Mechanisms of Pharmacological Action; Anticarcinogenic Agents; Antineoplastic Agents